Cancer-Associated Thrombosis: Trends in Clinical Features, Treatment, and Outcomes From 2001 to 2020
Authors' conclusion
In this multicenter study of cancer patients with VTE, there was a decline in thrombotic, hemorrhagic, and fatal events from 2001 to 2020.
Study context
- Population
- Patients with cancer-associated thrombosis in the RIETE registry, 2001–2020
- Participants
- 17,271 patients
- Exposure
- Temporal trends 2001–2020
- Outcome
- Risk-adjusted rates of symptomatic VTE recurrence, major bleeding and death
- Follow-up
- 30 days after incident VTE
Methodological detailsmulticenter, multivariable survival regression
- Multicenter
- Multivariable survival regression
Main finding
As reported in the abstract
Symptomatic VTE recurrence, major bleeding and death within 30 days, trends 2001–2020
Per yearEstimate (95% CI)
VTE recurrence
asHR 0.94(0.92–0.98)
Major bleeding
asHR 0.98(0.96–0.99)
Death
aHR 0.97(0.96–0.98)
Per year, as printed
- Symptomatic venous thromboembolism (VTE) recurrence at 30 days, 2001-2005 to 2016-2020
- from 3.1% to 1.1%; P < 0.001
- Major bleeding at 30 days, 2001-2005 to 2016-2020
- from 3.1% to 2.2%; P = 0.004
- Death at 30 days, 2001-2005 to 2016-2020
- from 11.9% to 8.4%; P < 0.001
Observational data: associations, not effects.
Further findings
Patient and treatment characteristics over time
PE at presentation
Lung cancer
Pancreatic cancer
Immunotherapy
Prostate cancer
Carcinoma of unknown origin
- Patient and treatment characteristics over time: PE P < 0.001 for trend; lung P < 0.001; pancreatic P = 0.003; immunotherapy P < 0.001; prostate P < 0.001; unknown origin P < 0.001
Original publication
Cancer-Associated Thrombosis: Trends in Clinical Features, Treatment, and Outcomes From 2001 to 2020. JACC CardioOncol. Published 15 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →